Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Potential Pathogenetic Role of Achromobacter (Alcaligenes) Xylosoxidans in Primary Extranodal Marginal Zone Lymphoma of the Lung (BALT-Lymphoma): Update of the Results of a Retrospective Analysis on Behalf of IELSG

Blood (2011) 118 (21): 880.

https://doi.org/10.1182/blood.V118.21.880.880

Published: 2011

Journal Articles

Final Results of a Multicenter Phase II Trial Assessing the Activity and Efficacy of Helicobacter Pylori -Eradicating Antibiotic Therapy As Exclusive Treatment for Patients with Stage I-II1 Diffuse Large B-Cell Lymphoma of the Stomach (the HGL-1 Trial)

Silvia Govi, MD, Caterina Patti, MD, Markus Raderer, MD, Alessandro Andriani, MD, Daniele Caracciolo, MD, Anna Guidetti, MD, Fiorella Ilariucci, MD, Stefano Luminari, MD, Antonino Mulè, MD, Edi Viale, MD, Paolo Giorgio Arcidiacono, MD, Maurilio Ponzoni, MD, Andrés J.M. Ferreri, MD

Blood (2011) 118 (21): 958.

https://doi.org/10.1182/blood.V118.21.958.958

Published: 2011

Journal Articles

Two-Monthly Rituximab Infusions Maintain Target Concentrations: Pharmacokinetic Data of the AGMT-NHL9 Maintenance Study in Patients with Follicular Lymphoma in Complete or Partial Remission.

Ulrich Jaeger, MD, Otto Krieger, MD, Georg Hopfinger, MD, Cathrin Skrabs, MD, Christine Einberger, Veronika Huter, MD, Hubert Hausmaninger, MD, Johannes Drach, MD, Markus Raderer, MD, Michael Woo, Pharm.D, Helen Melzer, PhD, Richard Greil, MD, Michael A Fridrik, MD

Blood (2008) 112 (11): 1997.

https://doi.org/10.1182/blood.V112.11.1997.1997

Published: 2008

Journal Articles

Bortezomib, Rituximab, and Dexamethason (BORID) as Salvage Treatment in Relapsed/Refractory Mantle Cell Lymphoma: Sustained Disease Control in Patients Achieving a Complete Remission.

Johannes Drach, MD, Hannes Kaufmann, MD, Oskar Pichelmayer, MD, Verena Sagaster, MD, Sonja Holzer, MD, Viktoria Odelga, MD, Christoph Zielinski, MD, Markus Raderer, MD

Blood (2007) 110 (11): 2578.

https://doi.org/10.1182/blood.V110.11.2578.2578

Published: 2007

Journal Articles

Marked Activity of Bortezomib, Rituximab, and Dexamethason in Relapsed and Refractory Mantle Cell Lymphoma.

Johannes Drach, MD, Hannes Kaufmann, MD, Oskar Pichelmayer, MD, Verena Sagaster, MD, Sonja Seidl, MD, Andreas Chott, MD, Christoph Zielinski, MD, Markus Raderer, MD

Blood (2006) 108 (11): 2753.

https://doi.org/10.1182/blood.V108.11.2753.2753

Published: 2006

Journal Articles

Predictive Value of Clonal Peripheral Blood γTCR Rearrangement in Patients with Peripheral T-Cell Lymphoma.

Christian Schuetzinger, Harald Esterbauer, MD,PhD, Cathrin Skrabs, MD, Martin Uffmann, MD, Markus Raderer, MD, Alexander Hauswirth, MD, Alexander Gaiger, MD, Christine Mannhalter, PhD, Karin Dieckmann, MD, Oswald Wagner, MD, Ulrich Jaeger, MD

Blood (2006) 108 (11): 2060.

https://doi.org/10.1182/blood.V108.11.2060.2060

Published: 2006

Journal Articles

Promising Activity of Bortezomib, Rituximab, and Dexamethason (BORID) in Patients with Relapsed Mantle Cell Lymphoma.

Johannes Drach, MD, Sonja Seidl, MD, Oskar Pichelmayer, MD, Hannes Kaufmann, MD, Christoph Zielinski, MD, Markus Raderer, MD

Blood (2005) 106 (11): 4799.

https://doi.org/10.1182/blood.V106.11.4799.4799

Published: 2005

Journal Articles

t(3;14)(P14.1;Q32) Involving IGH and FOXP1 Is a Recurrent Chromosomal Aberration in MALT Lymphoma.

Berthold Streubel, MD, Ursula Vinatzer, PhD, Andrea Lamprecht, Markus Raderer, MD, Andreas Chott, MD

Blood (2004) 104 (11): 550.

https://doi.org/10.1182/blood.V104.11.550.550

Published: 2004

NARROW

Potential Pathogenetic Role of Achromobacter (Alcaligenes) Xylosoxidans in Primary Extranodal Marginal Zone Lymphoma of the Lung (BALT-Lymphoma): Update of the Results of a Retrospective Analysis on Behalf of IELSG

Final Results of a Multicenter Phase II Trial Assessing the Activity and Efficacy of Helicobacter Pylori -Eradicating Antibiotic Therapy As Exclusive Treatment for Patients with Stage I-II1 Diffuse Large B-Cell Lymphoma of the Stomach (the HGL-1 Trial)

Two-Monthly Rituximab Infusions Maintain Target Concentrations: Pharmacokinetic Data of the AGMT-NHL9 Maintenance Study in Patients with Follicular Lymphoma in Complete or Partial Remission.

Bortezomib, Rituximab, and Dexamethason (BORID) as Salvage Treatment in Relapsed/Refractory Mantle Cell Lymphoma: Sustained Disease Control in Patients Achieving a Complete Remission.

Marked Activity of Bortezomib, Rituximab, and Dexamethason in Relapsed and Refractory Mantle Cell Lymphoma.

Predictive Value of Clonal Peripheral Blood γTCR Rearrangement in Patients with Peripheral T-Cell Lymphoma.

Promising Activity of Bortezomib, Rituximab, and Dexamethason (BORID) in Patients with Relapsed Mantle Cell Lymphoma.

t(3;14)(P14.1;Q32) Involving IGH and FOXP1 Is a Recurrent Chromosomal Aberration in MALT Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only